Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, The Lancet HIV, 9(9), p. e627-e637, 2022

DOI: 10.1016/s2352-3018(22)00160-6

Links

Tools

Export citation

Search in Google Scholar

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Journal article published in 2022 by Anna Turkova, Hylke Waalewijn, Man K. Chan, Pauline D. J. Bollen, Mutsa F. Bwakura-Dangarembizi, Adeodata R. Kekitiinwa, Mark F. Cotton, Abbas Lugemwa, Ebrahim Variava, Grace Miriam Ahimbisibwe, Ussanee Srirompotong, Vivian Mumbiro, Pauline Amuge, Peter Zuidewind, Shabinah Ali and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO